Need help finding what you are looking for?
Contact Us
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1437505
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1437505
Methicillin-resistant Staphylococcus Aureus Drugs Market, By Drug Class, By MRSA Types, By Disease Indication, By End Use, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
PUBLISHED:
PAGES: 316 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
REPORT HIGHLIGHT
Methicillin-resistant Staphylococcus Aureus Drugs Market size was valued at USD 2,050 Million in 2023, expanding at a CAGR of 5.4% from 2024 to 2032.
Methicillin-resistant Staphylococcus aureus, commonly known as MRSA, is a type of bacteria that has developed resistance to many antibiotics, including methicillin, which are commonly used to treat Staphylococcus aureus infections. This resistance makes MRSA infections more challenging to treat compared to infections caused by non-resistant strains of Staphylococcus aureus.
Methicillin-resistant Staphylococcus Aureus Drugs Market- Market Dynamics
Increasing prevalence of infections with methicillin-resistant staphylococcus aureus to propel market demand
The market for methicillin-resistant Staphylococcus aureus (MRSA) drugs has grown significantly as a result of a global increase in the prevalence of MRSA infections. The research "Methicillin-Resistant Staphylococcus Aureus," published in April 2023, suggests that MRSA may increase mortality and morbidity in elderly individuals, patients in nursing homes, and individuals with organ failure. Hospital-associated methicillin-resistant Staphylococcus aureus poses a significant risk of infection to patients receiving intensive care unit (ICU) admissions, renal failure patients, and patients with end-stage liver disease. The findings show that mortality rates vary from 5 to 60% based on the kind of patient and site of infection. Furthermore, even if there are no health dangers, more than 60% of patients get MRSA within 48 hours of being admitted to the hospital, according to a study.
Methicillin-resistant Staphylococcus Aureus Drugs Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.4% over the forecast period (2024-2032)
Based on drug class segmentation, glycopeptide was predicted to show maximum market share in the year 2023
Based on MRSA types segmentation, Hospital-acquired (HA-MRSA) was the leading type in 2023
Based on region, North America was the leading revenue generator in 2023
Methicillin-resistant Staphylococcus Aureus Drugs Market- Segmentation Analysis:
The Global Methicillin-resistant Staphylococcus Aureus Drugs Market is segmented based on Drug Class, MRSA Types, Disease Indication, End Use, and Region.
The market is divided into seven categories based on drug class: sulfa drugs, tetracyclines, oxazolidinones, folate antagonists, lipopeptide, glycopeptide antibiotics and others. The glycopeptide sector dominates the market. This is explained by the fact that glycopeptide antibiotics, such as the antitumor antibiotic bleomycin and the anti-infective antibiotics ramoplanin and decaplanin, teicoplanin, vancomycin, telavancin, corbomycin, and complestatin, are widely available.
The market is divided into two categories based on MRSA types: Hospital-acquired (HA-MRSA) and Community-acquired (CA-MRSA). The Hospital-acquired (HA-MRSA) sector dominates the market and is likely to maintain its dominance during the forecast period. This is explained by the rise in hospital-acquired illnesses. Hospitals are breeding grounds for germs and viruses, and following surgery, MRSA infection is a prevalent issue. MRSA is responsible for 10% of hospital-related infections in the United States, and these infections are connected with a greater risk of death. Therefore, it is projected that a rise in hospital surgical operations will propel segment expansion.
Methicillin-resistant Staphylococcus Aureus Drugs Market- Geographical Insights
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the market during the forecast period. This is explained by the large number of regional businesses that are actively involved in the study and creation of MRSA-resistant medications for the treatment of MRSA-related infections in healthcare environments. Some of the major businesses that sell their products in North America include Novartis AG, Proctor & Gamble, GSK plc, and Pfizer Inc. Therefore, it is expected that creating and releasing novel medications in the United States and Canada will expand the local market.
Methicillin-resistant Staphylococcus Aureus Drugs Market- Competitive Landscape:
The market players operating in the Methicillin-resistant Staphylococcus Aureus Drugs market are Melinta Therapeutics Inc, Pfizer Inc, Cumberland Pharmaceuticals Inc, AbbVie Inc., Merck & Co Inc, Theravance Biopharma, Nabriva Therapeutics Plc, Basilea Pharmaceutica, AmpliPhi Biosciences Corporation, Teva Pharmaceutical Industries ltd, Debiopharm International S.A., Innovation Pharmaceuticals Inc. and Paratek Pharmaceuticals, Inc. among others. These players adopted various strategies to hold a maximum market share such as product launches, acquisitions, expansion and others.
Recent Developments:
In October 2023, a commercial-stage biopharmaceutical company devoted to treating patients with severe bacterial or fungal infections, Basilea Pharmaceutica Ltd., Allschwil, announced that the US Food and Drug Administration (FDA) has accepted the submission of the New Drug Application (NDA) for the antibiotic ceftobiprole, which was made on August 3rd of this year. Basilea is requesting clearance through its NDA to treat patients for three indications: community-acquired bacterial pneumonia (CABP), acute bacterial skin and skin structure infections (ABSSSI), and Staphylococcus aureus bacteremia (SAB), which includes right-sided infective endocarditis.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
Melinta Therapeutics Inc
Pfizer Inc
Cumberland Pharmaceuticals Inc
AbbVie Inc
Merck & Co Inc
Theravance Biopharma
Nabriva Therapeutics Plc
Basilea Pharmaceutica
AmpliPhi Biosciences Corporation
Teva Pharmaceutical Industries Ltd
Debiopharm International S.A.
Innovation Pharmaceuticals Inc.
Paratek Pharmaceuticals, Inc.
GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032
- Sulfa Drugs
- Tetracyclines
- Oxazolidinones
- Folate Antagonists
- Lipopeptide
- Glycopeptide Antibiotics
- Others
GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY MRSA TYPES- MARKET ANALYSIS, 2019 - 2032
- Hospital-acquired (HA-MRSA)
- Community-acquired (CA-MRSA)
GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY DISEASE INDICATION- MARKET ANALYSIS, 2019 - 2032
- Skin Infections
- Bone and Joint Infections and Bacteremia
- Animal Infections
GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY END USE- MARKET ANALYSIS, 2019 - 2032
- Hospitals and Clinics
- Research and Academic Institutes
GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Netherlands
- Sweden
- Poland
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Australia
- Thailand
- Indonesia
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Product Code: ANV2223
Table of Contents
1. Methicillin-resistant Staphylococcus Aureus Drugs Market Overview
- 1.1. Study Scope
- 1.2. Market Estimation Years
2. Executive Summary
- 2.1. Market Snippet
- 2.1.1. Methicillin-resistant Staphylococcus Aureus Drugs Market Snippet by Drug Class
- 2.1.2. Methicillin-resistant Staphylococcus Aureus Drugs Market Snippet by MRSA Types
- 2.1.3. Methicillin-resistant Staphylococcus Aureus Drugs Market Snippet by Disease Indication
- 2.1.4. Methicillin-resistant Staphylococcus Aureus Drugs Market Snippet by End Use
- 2.1.5. Methicillin-resistant Staphylococcus Aureus Drugs Market Snippet by Country
- 2.1.6. Methicillin-resistant Staphylococcus Aureus Drugs Market Snippet by Region
- 2.2. Competitive Insights
3. Methicillin-resistant Staphylococcus Aureus Drugs Key Market Trends
- 3.1. Methicillin-resistant Staphylococcus Aureus Drugs Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
- 3.2. Methicillin-resistant Staphylococcus Aureus Drugs Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
- 3.3. Methicillin-resistant Staphylococcus Aureus Drugs Market Opportunities
- 3.4. Methicillin-resistant Staphylococcus Aureus Drugs Market Future Trends
4. Methicillin-resistant Staphylococcus Aureus Drugs Industry Study
- 4.1. PEST Analysis
- 4.2. Porter's Five Forces Analysis
- 4.3. Growth Prospect Mapping
- 4.4. Regulatory Framework Analysis
5. Methicillin-resistant Staphylococcus Aureus Drugs Market: COVID-19 Impact Analysis
- 5.1. Pre-COVID-19 Impact Analysis
- 5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments
6. Methicillin-resistant Staphylococcus Aureus Drugs Market Landscape
- 6.1. Methicillin-resistant Staphylococcus Aureus Drugs Market Share Analysis, 2023
- 6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis
7. Methicillin-resistant Staphylococcus Aureus Drugs Market - By Drug Class
- 7.1. Overview
- 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
- 7.1.2. Sulfa Drugs
- 7.1.3. Tetracyclines
- 7.1.4. Oxazolidinones
- 7.1.5. Folate Antagonists
- 7.1.6. Lipopeptide
- 7.1.7. Glycopeptide Antibiotics
- 7.1.8. Others
8. Methicillin-resistant Staphylococcus Aureus Drugs Market - By MRSA Types
- 8.1. Overview
- 8.1.1. Segment Share Analysis, By MRSA Types, 2023 & 2032 (%)
- 8.1.2. Hospital-acquired (HA-MRSA)
- 8.1.3. Community-acquired (CA-MRSA)
9. Methicillin-resistant Staphylococcus Aureus Drugs Market - By Disease Indication
- 9.1. Overview
- 9.1.1. Segment Share Analysis, By Disease Indication, 2023 & 2032 (%)
- 9.1.2. Skin Infections
- 9.1.3. Bone and Joint Infections and Bacteremia
- 9.1.4. Animal Infections
10. Methicillin-resistant Staphylococcus Aureus Drugs Market - By End Use
- 10.1. Overview
- 10.1.1. Segment Share Analysis, By End Use, 2023 & 2032 (%)
- 10.1.2. Hospitals and Clinics
- 10.1.3. Research and Academic Institutes
11. Methicillin-resistant Staphylococcus Aureus Drugs Market- By Geography
- 11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
- 11.2. North America
- 11.2.1. Overview
- 11.2.2. Methicillin-resistant Staphylococcus Aureus Drugs Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.2.8. U.S.
- 11.2.8.1. Overview
- 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.2.8.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.2.8.4. U.S. Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.2.8.5. U.S. Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.2.8.6. U.S. Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.2.9. Canada
- 11.2.9.1. Overview
- 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.2.9.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.2.9.4. Canada Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.2.9.5. Canada Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.2.9.6. Canada Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.3. Europe
- 11.3.1. Overview
- 11.3.2. Methicillin-resistant Staphylococcus Aureus Drugs Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.3.8. Germany
- 11.3.8.1. Overview
- 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.3.8.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.3.8.4. Germany Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.3.8.5. Germany Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.3.8.6. Germany Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.3.9. Italy
- 11.3.9.1. Overview
- 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.3.9.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.3.9.4. Italy Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.3.9.5. Italy Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.3.9.6. Italy Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.3.10. United Kingdom
- 11.3.10.1. Overview
- 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.3.10.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.3.10.4. United Kingdom Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.3.10.5. United Kingdom Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.3.10.6. United Kingdom Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.3.11. France
- 11.3.11.1. Overview
- 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.3.11.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.3.11.4. France Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.3.11.5. France Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.3.11.6. France Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.3.12. Russia
- 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.3.12.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.3.12.3. Russia Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.3.12.4. Russia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.3.12.5. Russia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.3.13. Netherlands
- 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.3.13.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.3.13.3. Netherlands Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.3.13.4. Netherlands Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.3.13.5. Netherlands Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.3.14. Sweden
- 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.3.14.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.3.14.3. Sweden Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.3.14.4. Sweden Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.3.14.5. Sweden Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.3.15. Poland
- 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.3.15.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.3.15.3. Poland Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.3.15.4. Poland Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.3.15.5. Poland Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.3.16. Rest of Europe
- 11.3.16.1. Overview
- 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.3.16.4. Rest of the Europe Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.3.16.5. Rest of the Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.3.16.6. Rest of the Europe Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Methicillin-resistant Staphylococcus Aureus Drugs Key Manufacturers in Asia Pacific
- 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.4.5. Asia Pacific Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.4.6. Asia Pacific Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.4.7. Asia Pacific Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.4.8. India
- 11.4.8.1. Overview
- 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.4.8.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.4.8.4. India Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.4.8.5. India Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.4.8.6. India Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.4.9. China
- 11.4.9.1. Overview
- 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.4.9.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.4.9.4. China Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.4.9.5. China Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.4.9.6. China Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.4.10. Japan
- 11.4.10.1. Overview
- 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.4.10.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.4.10.4. Japan Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.4.10.5. Japan Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.4.10.6. Japan Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.4.11. South Korea
- 11.4.11.1. Overview
- 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.4.11.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.4.11.4. South Korea Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.4.11.5. South Korea Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.4.11.6. South Korea Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.4.12. Australia
- 11.4.12.1. Overview
- 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.4.12.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.4.12.4. Australia Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.4.12.5. Australia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.4.12.6. Australia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.4.13. Thailand
- 11.4.13.1. Overview
- 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.4.13.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.4.13.4. Thailand Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.4.13.5. Thailand Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.4.13.6. Thailand Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.4.14. Indonesia
- 11.4.14.1. Overview
- 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.4.14.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.4.14.4. Indonesia Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.4.14.5. Indonesia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.4.14.6. Indonesia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.4.15. Philippines
- 11.4.15.1. Overview
- 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.4.15.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.4.15.4. Philippines Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.4.15.5. Philippines Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.4.15.6. Philippines Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.4.16. Rest of APAC
- 11.4.16.1. Overview
- 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.4.16.4. Rest of APAC Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.4.16.5. Rest of APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.4.16.6. Rest of APAC Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.5. Latin America
- 11.5.1. Overview
- 11.5.2. Methicillin-resistant Staphylococcus Aureus Drugs Key Manufacturers in Latin America
- 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.5.5. Latin America Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.5.6. Latin America Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.5.7. Latin America Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.5.8. Brazil
- 11.5.8.1. Overview
- 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.5.8.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.5.8.4. Brazil Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.5.8.5. Brazil Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.5.8.6. Brazil Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.5.9. Mexico
- 11.5.9.1. Overview
- 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.5.9.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.5.9.4. Mexico Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.5.9.5. Mexico Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.5.9.6. Mexico Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.5.10. Argentina
- 11.5.10.1. Overview
- 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.5.10.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.5.10.4. Argentina Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.5.10.5. Argentina Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.5.10.6. Argentina Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.5.11. Colombia
- 11.5.11.1. Overview
- 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.5.11.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.5.11.4. Colombia Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.5.11.5. Colombia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.5.11.6. Colombia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.5.12. Rest of LATAM
- 11.5.12.1. Overview
- 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.5.12.4. Rest of LATAM Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.5.12.5. Rest of LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.5.12.6. Rest of LATAM Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.6. Middle East and Africa
- 11.6.1. Overview
- 11.6.2. Methicillin-resistant Staphylococcus Aureus Drugs Key Manufacturers in Middle East and Africa
- 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.6.5. Middle East and Africa Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.6.6. Middle East and Africa Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.6.7. Middle East and Africa Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.6.8. Saudi Arabia
- 11.6.8.1. Overview
- 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.6.8.4. Saudi Arabia Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.6.8.5. Saudi Arabia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.6.8.6. Saudi Arabia Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.6.9. United Arab Emirates
- 11.6.9.1. Overview
- 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.6.9.4. United Arab Emirates Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.6.9.5. United Arab Emirates Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.6.9.6. United Arab Emirates Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.6.10. Israel
- 11.6.10.1. Overview
- 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.6.10.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.6.10.4. Israel Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.6.10.5. Israel Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.6.10.6. Israel Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.6.11. Turkey
- 11.6.11.1. Overview
- 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.6.11.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.6.11.4. Turkey Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.6.11.5. Turkey Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.6.11.6. Turkey Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.6.12. Algeria
- 11.6.12.1. Overview
- 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.6.12.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.6.12.4. Algeria Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.6.12.5. Algeria Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.6.12.6. Algeria Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.6.13. Egypt
- 11.6.13.1. Overview
- 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.6.13.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.6.13.4. Egypt Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.6.13.5. Egypt Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.6.13.6. Egypt Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
- 11.6.14. Rest of MEA
- 11.6.14.1. Overview
- 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
- 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
- 11.6.14.4. Rest of MEA Market Size and Forecast, By MRSA Types, 2019 - 2032 (US$ Million)
- 11.6.14.5. Rest of MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
- 11.6.14.6. Rest of MEA Market Size and Forecast, By End Use, 2019 - 2032 (US$ Million)
12. Key Vendor Analysis- Methicillin-resistant Staphylococcus Aureus Drugs Industry
- 12.1. Competitive Dashboard
- 12.2. Company Profiles
- 12.2.1. Melinta Therapeutics Inc
- 12.2.2. Pfizer Inc
- 12.2.3. Cumberland Pharmaceuticals Inc
- 12.2.4. AbbVie Inc
- 12.2.5. Merck & Co Inc
- 12.2.6. Theravance Biopharma
- 12.2.7. Nabriva Therapeutics Plc
- 12.2.8. Basilea Pharmaceutica
- 12.2.9. AmpliPhi Biosciences Corporation
- 12.2.10. Teva Pharmaceutical Industries ltd
- 12.2.11. Debiopharm International S.A.
- 12.2.12. Innovation Pharmaceuticals Inc.
- 12.2.13. Paratek Pharmaceuticals, Inc.
13. 360 Degree Analyst View
14. Appendix
- 14.1. Research Methodology
- 14.2. References
- 14.3. Abbreviations
- 14.4. Disclaimer
- 14.5. Contact Us
Product Code: ANV2223
List of Tables
- TABLE List of data sources
- TABLE Market drivers; Impact Analysis
- TABLE Market restraints; Impact Analysis
- TABLE Methicillin-resistant Staphylococcus Aureus Drugs Market: Drug Class Snapshot (2023)
- TABLE Segment Dashboard; Definition and Scope, by Drug Class
- TABLE Global Methicillin-resistant Staphylococcus Aureus Drugs Market, by Drug Class 2019-2032 (USD Million)
- TABLE Methicillin-resistant Staphylococcus Aureus Drugs Market: MRSA Types Snapshot (2023)
- TABLE Segment Dashboard; Definition and Scope, by MRSA Types
- TABLE Global Methicillin-resistant Staphylococcus Aureus Drugs Market, by MRSA Types 2019-2032 (USD Million)
- TABLE Methicillin-resistant Staphylococcus Aureus Drugs Market: Disease Indication Snapshot (2023)
- TABLE Segment Dashboard; Definition and Scope, by Disease Indication
- TABLE Global Methicillin-resistant Staphylococcus Aureus Drugs Market, by Disease Indication 2019-2032 (USD Million)
- TABLE Methicillin-resistant Staphylococcus Aureus Drugs Market: End Use Snapshot (2023)
- TABLE Segment Dashboard; Definition and Scope, by End Use
- TABLE Global Methicillin-resistant Staphylococcus Aureus Drugs Market, by End Use 2019-2032 (USD Million)
- TABLE Methicillin-resistant Staphylococcus Aureus Drugs Market: Regional snapshot (2023)
- TABLE Segment Dashboard; Definition and Scope, by Region
- TABLE Global Methicillin-resistant Staphylococcus Aureus Drugs Market, by Region 2019-2032 (USD Million)
- TABLE North America Methicillin-resistant Staphylococcus Aureus Drugs Market, by Country, 2019-2032 (USD Million)
- TABLE North America Methicillin-resistant Staphylococcus Aureus Drugs Market, by Drug Class, 2019-2032 (USD Million)
- TABLE North America Methicillin-resistant Staphylococcus Aureus Drugs Market, by MRSA Types, 2019-2032 (USD Million)
- TABLE North America Methicillin-resistant Staphylococcus Aureus Drugs Market, by Disease Indication, 2019-2032 (USD Million)
- TABLE North America Methicillin-resistant Staphylococcus Aureus Drugs Market, by End Use, 2019-2032 (USD Million)
- TABLE Europe Methicillin-resistant Staphylococcus Aureus Drugs Market, by Country, 2019-2032 (USD Million)
- TABLE Europe Methicillin-resistant Staphylococcus Aureus Drugs Market, by Drug Class, 2019-2032 (USD Million)
- TABLE Europe Methicillin-resistant Staphylococcus Aureus Drugs Market, by MRSA Types, 2019-2032 (USD Million)
- TABLE Europe Methicillin-resistant Staphylococcus Aureus Drugs Market, by Disease Indication, 2019-2032 (USD Million)
- TABLE Europe Methicillin-resistant Staphylococcus Aureus Drugs Market, by End Use, 2019-2032 (USD Million)
- TABLE Asia Pacific Methicillin-resistant Staphylococcus Aureus Drugs Market, by Country, 2019-2032 (USD Million)
- TABLE Asia Pacific Methicillin-resistant Staphylococcus Aureus Drugs Market, by Drug Class, 2019-2032 (USD Million)
- TABLE Asia Pacific Methicillin-resistant Staphylococcus Aureus Drugs Market, by MRSA Types, 2019-2032 (USD Million)
- TABLE Asia Pacific Methicillin-resistant Staphylococcus Aureus Drugs Market, by Disease Indication, 2019-2032 (USD Million)
- TABLE Asia Pacific Methicillin-resistant Staphylococcus Aureus Drugs Market, by End Use, 2019-2032 (USD Million)
- TABLE Latin America Methicillin-resistant Staphylococcus Aureus Drugs Market, by Country, 2019-2032 (USD Million)
- TABLE Latin America Methicillin-resistant Staphylococcus Aureus Drugs Market, by Drug Class, 2019-2032 (USD Million)
- TABLE Latin America Methicillin-resistant Staphylococcus Aureus Drugs Market, by MRSA Types, 2019-2032 (USD Million)
- TABLE Latin America Methicillin-resistant Staphylococcus Aureus Drugs Market, by Disease Indication, 2019-2032 (USD Million)
- TABLE Latin America Methicillin-resistant Staphylococcus Aureus Drugs Market, by End Use, 2019-2032 (USD Million)
- TABLE Middle East and Africa Methicillin-resistant Staphylococcus Aureus Drugs Market, by Country, 2019-2032 (USD Million)
- TABLE Middle East and Africa Methicillin-resistant Staphylococcus Aureus Drugs Market, by Drug Class, 2019-2032 (USD Million)
- TABLE Middle East and Africa Methicillin-resistant Staphylococcus Aureus Drugs Market, by MRSA Types, 2019-2032 (USD Million)
- TABLE Middle East and Africa Methicillin-resistant Staphylococcus Aureus Drugs Market, by Disease Indication, 2019-2032 (USD Million)
- TABLE Middle East and Africa Methicillin-resistant Staphylococcus Aureus Drugs Market, by End Use, 2019-2032 (USD Million)
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.